Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Tasigna (nilotinib by Year
Tasigna (nilotinib — chronic myeloid leukemia CML) ($M)
Novartis Tasigna (nilotinib: $1,104M in FY2025, down 33.9% from a year earlier. That is the lowest of the 9 years on record here.
Latest, FY2025
1,104
Period ended Dec 31, 2025
Change on a year earlier
-33.9%
1,671 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Where the FY2025 figure comes from
“|| Tasigna | 1 104 | 1 671 | -34 | -34”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tasigna (nilotinib — chronic myeloid leukemia CML) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,104 | -33.9% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,671 | -9.6% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,848 | -3.9% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,923 | -6.7% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 2,060 | +5.2% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 1,958 | +4.1% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 1,880 | +0.3% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 1,874 | +1.8% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 1,841 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up tasigna (nilotinib
Cite this data
StockData. (2026). Novartis Tasigna (nilotinib ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-tasigna
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.